4.7 Article

Predicting solution aggregation rates for therapeutic proteins: Approaches and challenges

Journal

INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 418, Issue 2, Pages 318-333

Publisher

ELSEVIER
DOI: 10.1016/j.ijpharm.2011.03.064

Keywords

Protein stability; Non-native aggregation; Modeling; Biotechnology

Funding

  1. Pfizer, Inc.

Ask authors/readers for more resources

Non-native aggregation is a common concern during therapeutic protein product development and manufacturing, particularly for liquid dosage forms. Because aggregates are often net irreversible under the conditions that they form, controlling aggregate levels requires control of aggregation rates across a range of solution conditions. Rational design of product formulation(s) would therefore benefit greatly from methods to accurately predict aggregation rates. This article focuses on the principles underlying current rate-prediction approaches for non-native aggregation, the limitations and strengths of different approaches, and illustrative examples from the authors' laboratories. The analysis highlights a number of reasons why accurate prediction of aggregation rates remains an outstanding challenge, and suggests some of the important areas for research to ultimately enable improved predictive capabilities in the future. (C) 2011 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available